IDH1 and central nervous system cancer: In IDH mutant gliomas, the immune scores of the high‐risk group were markedly higher than that of the low‐risk group, whereas in IDH wild‐type gliomas, the immune scores of the high‐risk and low‐risk groups did not differ significantly (Figure S5).